Aligos Therapeutics (NASDAQ:ALGS) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a report released on Thursday, MarketBeat reports. The firm issued a buy rating and a $48.00 price objective on the stock.

ALGS has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen downgraded Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. UBS Group assumed coverage on Aligos Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Aligos Therapeutics in a research report on Wednesday, March 11th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Aligos Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

Aligos Therapeutics Trading Up 5.6%

NASDAQ:ALGS opened at $7.34 on Thursday. The firm has a market capitalization of $45.43 million, a PE ratio of -0.85 and a beta of 2.67. Aligos Therapeutics has a 1 year low of $3.76 and a 1 year high of $13.69. The firm’s fifty day simple moving average is $7.53 and its 200 day simple moving average is $8.89.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.09) by $0.18. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.27 million. As a group, analysts anticipate that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Aligos Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. grew its stake in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares during the period. XTX Topco Ltd bought a new position in shares of Aligos Therapeutics during the 4th quarter worth approximately $215,000. SummitTX Capital L.P. acquired a new stake in Aligos Therapeutics in the 4th quarter valued at $1,299,000. Verition Fund Management LLC acquired a new stake in Aligos Therapeutics in the 4th quarter valued at $664,000. Finally, Marshall Wace LLP bought a new stake in Aligos Therapeutics in the fourth quarter valued at $2,504,000. 60.43% of the stock is owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.